Fusion Pharmaceuticals raises $25M in Series A from J&J for cancer radiotherapeutics – BioPharma Daily # 184
Fusion Pharmaceuticals launches with a $25M Series A financing to develop targeted Radiotherapeutics as Cancer Treatments.
PMV Pharma secures $74M in Series B financing for cancer drugs targeting p53 – BioPharma Daily # 183
PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, announced the completion of a $74M Series B financing round.
Cashing in on Duchenne approval, Sarepta sells voucher to Gilead for $125M.
AstraZeneca, TerSera enter deal for anti-cancer drug Zoladex; TerSera to pay AstraZeneca $250M.